Catch runners before the crowd AND track dilution on every stock. Share count changes, float risk, offering activity. $7/day. 100% money back.

Decoy Therapeutics (DCOY) will present at The Small Cap Showcase in New York City on October 1, 2026. Chief Executive Officer Rick Pierce will deliver a corporate overview at 11:30 a.m. ET and participate in one-on-one meetings with investors during the conference.

$DCOY: Decoy reports seven-day preclinical DCOY-CoV tissue exposure. Weekly dosing remains a hypothesis; 2027 clinical plans and financing risks explained.

Catch runners before the crowd AND track dilution on every stock. Share count changes, float risk, offering activity. $7/day. 100% money back.

Decoy Therapeutics has shared groundbreaking preclinical data suggesting a weekly intranasal dosing regimen for its DCOY-CoV initiative, maintaining drug efficacy for up to a week.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Click to view the official SEC document.

Using AI to find stock market opportunities. Click to read StockQuakes, by StockQuakes Team, a Substack publication with thousands of subscribers.

Decoy Therapeutics, Inc. recently corrected a statement regarding warrant inducement transactions, clarifying the terms of new warrants issued.

Decoy Therapeutics (DCOY) corrected details of its previously announced warrant inducement transaction dated September 22, 2026. The company now states that the new unregistered warrants to purchase up to 2,368,868 shares of common stock will become exercisable immediately upon issuance, rather than upon receipt of stockholder approval as previously indicated.The new warrants are not subject to stockholder approval and will expire five years from their issuance date. All other terms and information from the original warrant inducement press release remain unchanged.